AZD2284

DRUG2 trials

Sponsors

AstraZeneca, AstraZeneca AB

Conditions

CancerMetastatic Castration-Resistant Prostate Cancer

Phase 1

A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer

RecruitingNCT06879041

AstraZenecaMetastatic Castration-Resistant Prostate Cancer

Start: 2025-03-10End: 2029-04-16Target: 136Updated: 2026-05-12

A Phase I, First-in-human, Dose Escalation Study Of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer

Active, not recruitingPACTR202607505608191

AstraZeneca ABCancer

Start: 2025-01-01Target: 31Updated: 2026-08-03